NCT00071006

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Phase 2 Study Of AG-013736 In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.

Conditions

• Acute Myeloid Leukemia (AML)
• Myelodysplastic Syndrome

Interventions

Type	Name	Description
DRUG	AG-013736 (Axitinib)	patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.

Timeline

• Start date: 2003-09-01
• Primary completion: 2004-07-01
• Completion: 2004-07-01
• First posted: 2003-10-13
• Last updated: 2012-06-08
• Results posted: 2012-03-19

Locations

1 site across 1 country: United States